Synthesis of substituted pyridine based sulphonamides as an antidiabetic agent

This research work describes the synthesis of a new series of heterocyclic compounds, namely sulfonamide derivatives. Sulfonamides are a diverse class of organic compounds having significant and potent biological activities. Diverse synthetic methods have been engaged to build up its various derivatives for different biological functions. In this study, the production of novel pyridine-based heterocyclic compounds having sulfonamide moieties has been elaborated. The obtained sulfonamide-based pyridine scaffold was used to investigate their alpha-amylase inhibition activity. The structures of freshly prepared compounds were described using 1H NMR, 13C NMR, and IR spectroscopic techniques. The molecular docking of sulfonamides performed against porcine pancreatic alpha-amylase using PDB file 1LP was used for generation of grid. All the new synthesized compounds were shown notable anti-diabetic activity

Synthesis, crystal structures and antimicrobial activity of palladium metal complexes of sulfonyl hydrazone ligands

Palladium complexes of sulfonyl hydrazone based ligands have been prepared by refluxing with the corresponding ligands and Pd(II) salt in 2:1 ratio. The compounds have been characterized by FT-IR and UV-Vis spectroscopic methods. The crystal structure of the prepared palladium complexes has been determined by single-crystal X-ray crystallographic technique. Crystal data for C40H50N4O6PdS2 (PMHT-Pd(II) complex): triclinic, space group P-1 (no. 2), a = 7.1561(6) Å, b = 12.1300(11) Å, c = 12.6117(17) Å, α = 63.498(11)°, β = 86.694(9)°, γ = 81.451(7)° and Z = 1. The final R1 was 0.0699 (I > 2σ(I)) and wR2 was 0.1834 (all data). Crystal data for C36H42N4O6PdS2 (PTHC-Pd(II) complex): monoclinic, space group P21/n (no. 14), a = 8.6726(2) Å, b = 20.8824(4) Å, c = 10.3351(2) Å, β = 104.429(2)° and Z = 2. The final R1 was 0.0344 (I > 2σ(I)) and wR2 was 0.0840 (all data). Crystal data for C36H42N4O6PdS2 (PTHT-Pd(II) complex): monoclinic, space group P21/n (no. 14), a = 9.7658(2) Å, b = 10.0488(3) Å, c = 18.7714(4) Å, β = 99.602(2)° and Z = 2. The final R1 was 0.0334 (I > 2σ(I)) and wR2 was 0.0832 (all data). Crystal data for C40H50N4O6PdS2 (PMHC-Pd(II) complex): triclinic, space group P-1 (no. 2), a = 10.2070(9) Å, b = 12.1841(13) Å, c = 16.8879(19) Å, α = 109.005(6)°, β = 90.061(5)°, γ = 99.032(5)° and Z = 2. The final R1 was 0.0822 (I > 2σ(I)) and wR2 was 0.2293 (all data). The single-crystal structure data showed a good agreement with the experimental results. The synthesized complexes were screened for their in vitro antibacterial activity against one Gram-negative (Escherichia coli) and two Gram-positive (Bacillus subtilis and Staphylococcus aureus) bacterial strains and for in vitro antifungal activity against Aspergillus niger, Aspergillus flavus and Aspergillus fumigatus. The PTHC-Pd(II) complex possesses the nearby significant antifungal activity analogous to the standard drug fluconazole against selected fungal strains Aspergillus niger, Aspergillus Flavus and Aspergillus fumigatus as well as the same complex showed the antibacterial activity for Staphylococcus aureus as comparable to standard ofloxacin drug